Repligen (RGEN) free cash flow

Free cash flow · fiscal 2025
$91.69M

Repligen (RGEN) generated free cash flow of $91.69M in fiscal 2025 (the year ended December 31, 2025). That is 35.7% lower than the $142.49M of fiscal 2024. Figures as of 18 Nov 2026, 12:21 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Free cash flow, fiscal 2025
$91.69M
Change on fiscal 2024
−35.7%
Growth, 5 years
+17.9% a year
Growth, 10 years
+22.1% a year
Highest on record
$142.49Mfiscal 2024
Lowest on record
-$3.05Mfiscal 2010
Fiscal years on record
162010–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Repligen free cash flow, in more detail

Over the five fiscal years to 2025 free cash flow grew at a compound 17.9% a year; over ten years the rate was 22.1% a year. Across the 16 fiscal years on record (2010–2025), the highest was $142.49M in fiscal 2024 and the lowest -$3.05M in fiscal 2010.

History · 16 fiscal years

Free cash flow by fiscal year

Repligen free cash flow, year by year

Repligen (RGEN) free cash flow by fiscal year
Fiscal yearFree cash flowChangeYear ended
2025$91.69M 35.7% down
2024$142.49M 90.2% up
2023$74.93M 93.4% up
2022$38.74M 25.4% down
2021$51.93M 29.3% up
2020$40.17M 17.5% down
2019$48.71M 120.1% up
2018$22.14M 84.5% up
2017$12.00M 275.4% up
2016$3.20M 74.3% down
2015$12.43M 2.9% down
2014$12.80M 39.9% down
2013$21.29M 74.9% up
2012$12.18M 349.8% up
2011$2.71M—
2010-$3.05M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Free cash flow is the cash generated by operations minus capital spending, both taken from the cash-flow statement.

How to read it

It is the cash left for dividends, buybacks, debt repayment and acquisitions; profit that never turns into free cash flow deserves a second look.

Free cash flow at health care companies of similar size

Free cash flow of Repligen and comparable companies
CompanyFree cash flowFiscal year
Kymera Therapeutics KYMR-$234.34M2025
DaVita DVA$1.31B2025
Halozyme Therapeutics HALO$356.82M2025
Universal Health Services UHS$824.55M2025
Repligen RGEN$91.69M2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on RGEN

Repligen, figure by figure

Repligen (RGEN) overview: price, valuation and scorecardAll health care companies by market value

Repligen free cash flow: questions and answers

What is Repligen's free cash flow?

Repligen (RGEN) generated free cash flow of $91.69M in fiscal 2025 (the year ended December 31, 2025). That is 35.7% lower than the $142.49M of fiscal 2024.

What is the growth rate of Repligen's free cash flow?

Over the five fiscal years to 2025 free cash flow grew at a compound 17.9% a year; over ten years the rate was 22.1% a year.

What are the highest and lowest free cash flow figures on record for Repligen?

Across the 16 fiscal years on record (2010–2025), the highest was $142.49M in fiscal 2024 and the lowest -$3.05M in fiscal 2010.

How is Repligen's free cash flow calculated?

Free cash flow is the cash generated by operations minus capital spending, both taken from the cash-flow statement. For Repligen it is on record here for 16 fiscal years, 2010 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Repligen (RGEN) free cash flow”, data as of 18 November 2026. https://funkfolio.com/stock/RGEN/free-cash-flow

Underlying data: the company's filings with the SEC and Yahoo Finance.